Showing results (401-410 of 414) with videos related to

Sort By:
Pageof 42
Science Immunology|January 16, 2021
Inhibitory signaling sustains a distinct early memory CD8+ T cell precursor that is resistant to DNA damageJonathan B Johnnidis, Yuki Muroyama, Shin Foong Ngiow, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 13, 2019
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
Nature|September 28, 2022
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion programMasao Hashimoto, Koichi Araki, Maria A Cardenas, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Science Translational Medicine|February 18, 2021
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responsesJennifer A Lo, Masayoshi Kawakubo, Vikram R Juneja, et al.
Pageof 42